Nifty
Sensex
:
:
11895.45
40356.69
23.35 (0.20%)
70.21 (0.17%)

Pharmaceuticals & Drugs

Rating :
60/99

BSE: 500257 | NSE: LUPIN

742.25
15-Nov-2019
  • Open
  • High
  • Low
  • Previous Close
  •  739.85
  •  747.80
  •  731.55
  •  738.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1106828
  •  8204.65
  •  906.00
  •  646.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 33,604.24
  • 107.09
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 41,113.19
  • 0.67%
  • 2.47

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.96%
  • 1.24%
  • 10.87%
  • FII
  • DII
  • Others
  • 0.41%
  • 12.81%
  • 27.71%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.13
  • 5.54
  • -1.50

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.35
  • -4.45
  • -8.50

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -1.32
  • -24.16
  • -38.16

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.26
  • 28.78
  • 23.10

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.48
  • 5.06
  • 3.22

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.88
  • 16.26
  • 13.27

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Net Sales
4,359.65
3,951.06
10.34%
4,418.38
3,855.93
14.59%
4,406.32
4,033.83
9.23%
4,504.87
3,975.62
13.31%
Expenses
3,628.62
3,401.42
6.68%
3,558.16
3,328.96
6.89%
3,534.03
3,325.08
6.28%
3,752.33
3,287.28
14.15%
EBITDA
731.03
549.64
33.00%
860.22
526.97
63.24%
872.29
708.75
23.07%
752.54
688.34
9.33%
EBIDTM
16.77%
13.91%
19.47%
13.67%
19.80%
17.57%
16.70%
17.31%
Other Income
133.27
230.68
-42.23%
72.21
184.20
-60.80%
86.50
144.92
-40.31%
43.42
28.42
52.78%
Interest
86.46
73.82
17.12%
85.62
68.72
24.59%
85.52
58.53
46.11%
79.77
54.00
47.72%
Depreciation
321.47
265.49
21.09%
317.09
258.98
22.44%
280.78
272.83
2.91%
279.76
280.35
-0.21%
PBT
-90.11
441.01
-
529.72
383.47
38.14%
594.73
-942.04
-
94.21
382.41
-75.36%
Tax
34.30
172.91
-80.16%
227.98
181.14
25.86%
299.84
-163.18
-
247.80
160.77
54.13%
PAT
-124.41
268.10
-
301.74
202.33
49.13%
294.89
-778.86
-
-153.59
221.64
-
PATM
-2.85%
6.79%
6.83%
5.25%
6.69%
-19.31%
-3.41%
5.58%
EPS
-2.81
5.88
-
6.70
4.48
49.55%
6.40
-17.33
-
-3.35
4.91
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
17,689.22
16,718.18
15,804.15
17,494.33
14,255.54
12,770.01
11,286.57
9,641.30
7,082.91
5,818.97
4,870.79
Net Sales Growth
11.84%
5.78%
-9.66%
22.72%
11.63%
13.14%
17.06%
36.12%
21.72%
19.47%
 
Cost Of Goods Sold
6,086.13
5,234.59
4,733.76
4,660.97
4,010.21
3,806.16
3,485.50
3,221.50
2,364.87
2,060.99
1,821.29
Gross Profit
11,603.09
11,483.59
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
3,757.98
3,049.50
GP Margin
65.59%
68.69%
70.05%
73.36%
71.87%
70.19%
69.12%
66.59%
66.61%
64.58%
62.61%
Total Expenditure
14,473.14
13,835.96
12,656.64
13,001.19
10,570.19
9,150.42
8,283.78
7,371.41
5,638.20
4,641.13
3,886.90
Power & Fuel Cost
-
475.51
433.88
377.86
381.27
362.81
334.29
320.22
268.82
205.47
154.66
% Of Sales
-
2.84%
2.75%
2.16%
2.67%
2.84%
2.96%
3.32%
3.80%
3.53%
3.18%
Employee Cost
-
3,151.29
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
767.56
549.96
% Of Sales
-
18.85%
18.13%
16.29%
15.02%
13.68%
12.98%
13.14%
13.69%
13.19%
11.29%
Manufacturing Exp.
-
2,030.42
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
603.68
500.14
% Of Sales
-
12.14%
13.21%
12.98%
12.39%
10.34%
10.01%
10.13%
10.63%
10.37%
10.27%
General & Admin Exp.
-
1,429.32
1,219.96
1,306.27
1,195.98
806.87
810.53
692.06
471.23
325.19
292.37
% Of Sales
-
8.55%
7.72%
7.47%
8.39%
6.32%
7.18%
7.18%
6.65%
5.59%
6.00%
Selling & Distn. Exp.
-
1,298.77
1,150.61
1,252.77
870.29
835.48
775.26
709.62
647.88
547.48
446.97
% Of Sales
-
7.77%
7.28%
7.16%
6.10%
6.54%
6.87%
7.36%
9.15%
9.41%
9.18%
Miscellaneous Exp.
-
216.06
166.20
283.61
204.82
271.21
283.96
184.88
162.80
130.76
446.97
% Of Sales
-
1.29%
1.05%
1.62%
1.44%
2.12%
2.52%
1.92%
2.30%
2.25%
2.49%
EBITDA
3,216.08
2,882.22
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
1,177.84
983.89
EBITDA Margin
18.18%
17.24%
19.92%
25.68%
25.85%
28.34%
26.60%
23.54%
20.40%
20.24%
20.20%
Other Income
335.40
364.02
150.35
106.51
185.19
239.75
116.48
27.85
14.35
22.19
14.20
Interest
337.37
307.83
204.35
152.53
59.47
9.81
26.65
40.95
35.47
34.48
38.49
Depreciation
1,199.10
1,085.01
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
171.18
123.91
PBT
1,128.55
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
Tax
809.92
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
114.98
136.02
Tax Rate
71.77%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
11.56%
16.28%
PAT
318.63
602.80
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
864.55
688.51
PAT before Minority Interest
312.75
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
879.39
699.67
Minority Interest
-5.88
-8.93
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
-14.84
-11.16
PAT Margin
1.80%
3.61%
1.57%
14.57%
15.82%
18.82%
16.27%
13.63%
12.25%
14.86%
14.14%
PAT Growth
467.13%
143.32%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
0.36%
25.57%
 
Unadjusted EPS
6.94
13.41
5.56
56.69
50.25
53.54
40.99
29.39
19.43
19.36
15.84

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
3,281.08
2,567.83
Share Capital
90.50
90.42
90.32
90.12
89.90
89.68
89.51
89.33
89.24
88.94
Total Reserves
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
3,190.59
2,478.35
Non-Current Liabilities
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
533.59
1,283.35
Secured Loans
358.82
448.03
217.15
5.55
12.50
24.42
37.95
27.76
54.25
872.24
Unsecured Loans
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
244.91
267.61
Long Term Provisions
370.79
356.85
308.73
190.00
162.03
132.49
112.45
77.02
37.28
0.00
Current Liabilities
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
2,507.37
1,189.25
Trade Payables
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
993.03
883.52
Other Current Liabilities
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
201.02
82.82
Short Term Borrowings
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
791.09
0.00
Short Term Provisions
771.66
551.23
569.39
325.67
574.26
345.40
355.97
316.86
522.23
222.91
Total Liabilities
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92
Net Block
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
2,056.83
1,906.17
Gross Block
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
2,964.34
2,613.39
Accumulated Depreciation
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
907.51
707.22
Non Current Assets
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
2,869.33
2,290.47
Capital Work in Progress
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
478.17
348.80
Non Current Investment
185.63
26.71
22.00
14.33
2.51
2.06
2.06
2.80
3.15
26.43
Long Term Loans & Adv.
402.61
383.00
950.76
960.22
274.20
372.99
387.36
396.94
314.42
0.00
Other Non Current Assets
47.13
9.38
7.96
7.70
0.32
0.00
0.00
0.00
4.52
0.00
Current Assets
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
3,504.22
2,775.45
Current Investments
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
0.00
0.00
Inventories
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
1,199.96
971.49
Sundry Debtors
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
1,255.64
1,126.57
Cash & Bank
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
420.14
201.53
Other Current Assets
1,769.95
621.30
533.43
479.44
534.98
532.99
572.33
427.17
628.48
475.86
Short Term Loans & Adv.
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
515.64
475.86
Net Current Assets
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
996.85
1,586.20
Total Assets
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
797.98
676.41
PBT
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
Adjustment
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
207.16
144.33
Changes in Working Capital
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
-159.56
-136.62
Cash after chg. in Working capital
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
1,041.97
843.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
-243.99
-166.99
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
-519.56
-680.17
Net Fixed Assets
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
-558.11
-309.75
Net Investments
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
43.19
-250.20
Others
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
-4.64
-120.22
Cash from Financing Activity
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
-162.52
136.13
Net Cash Inflow / Outflow
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
115.90
132.37
Opening Cash & Equivalents
1,416.43
687.47
780.22
2,095.06
606.62
310.93
244.65
295.88
164.22
68.08
Closing Cash & Equivalent
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62
310.93
244.65
295.88
197.99

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
298.87
295.64
295.04
245.21
196.17
154.00
116.13
89.78
73.51
57.73
ROA
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
15.37%
15.44%
ROE
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
30.08%
35.05%
ROCE
8.48%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
25.24%
27.51%
Fixed Asset Turnover
1.95
2.07
1.62
1.80
2.15
2.28
2.19
1.99
2.10
2.06
Receivable days
65.46
63.76
92.39
92.24
72.65
74.67
74.61
77.76
74.26
76.18
Inventory Days
47.47
49.03
72.15
73.96
65.73
65.48
69.24
75.12
67.69
71.86
Payable days
59.26
68.56
59.62
63.20
64.43
63.78
63.76
64.11
61.46
64.47
Cash Conversion Cycle
53.67
44.23
104.91
103.00
73.94
76.37
80.10
88.76
80.49
83.57
Total Debt/Equity
0.63
0.53
0.60
0.65
0.06
0.09
0.22
0.41
0.35
0.44
Interest Cover
5.92
3.66
24.18
56.89
349.10
107.25
48.00
34.72
29.84
22.71

News Update:


  • Lupin to divest entire stake in Kyowa Pharmaceutical
    12th Nov 2019, 09:10 AM

    The Board of Directors of the Company at its meeting held on November 11, 2019 has approved the same

    Read More
  • Lupin receives USFDA’s nod for Zileuton Extended-Release Tablets
    11th Nov 2019, 08:57 AM

    Zileuton Extended-Release Tablets, 600 mg had annual sales of approximately $43 million in the US

    Read More
  • Lupin reports net loss of Rs 127 crore in Q2FY20
    6th Nov 2019, 15:37 PM

    Total consolidated income of the company increased by 3.97% at Rs 2,293.75 crore for Q2FY20

    Read More
  • Lupin - Quarterly Results
    6th Nov 2019, 14:57 PM

    Read More
  • Lupin receives USFDA's approval for Levothyroxine Sodium Tablets
    1st Nov 2019, 15:25 PM

    Levothyroxine Sodium Tablets USP had annual sales of approximately $2,581 million in the US

    Read More
  • Lupin receives USFDA's approval for Divalproex Sodium ER Tablets USP
    22nd Oct 2019, 15:57 PM

    Divalproex Sodium Extended-Release Tablets USP, 250 mg and 500 mg had annual sales of approximately $159 million in the U.S

    Read More
  • Lupin receives EIR from USFDA for Nagpur facility
    18th Oct 2019, 15:10 PM

    The inspection for the oral solid facility at Nagpur closed without any Form 483 observation

    Read More
  • Lupin gets GMP Certificate from Japan’s PMDA for Mandideep API facility
    9th Oct 2019, 11:41 AM

    The GMP Certificate issued by PMDA for Mandideep facility (Unit II) is valid till September 2024

    Read More
  • Lupin gets red flag from USFDA for significant violations in manufacturing practice
    5th Oct 2019, 12:53 PM

    USFDA has red flagged to the company’s Mandideep facility in Madhya Pradesh

    Read More
  • Lupin launches Mycophenolate Mofetil Capsules
    4th Oct 2019, 16:22 PM

    The company’s alliance partner Concord Biotech had received an approval from the USFDA earlier

    Read More
  • Lupin receives USFDA's approval for Extended Phenytoin Sodium Capsules
    1st Oct 2019, 15:07 PM

    Extended Phenytoin Sodium Capsules USP, 100 mg had annual sales of approximately $105 million in the US

    Read More
  • Japan’s PMDA completes GMP inspection at Lupin’s Goa facility
    30th Sep 2019, 16:07 PM

    The PMDA inspection closed with no critical or major observations

    Read More
  • Lupin launches Sildenafil Tablets
    30th Sep 2019, 15:37 PM

    Sildenafil Tablets are a phosphodiesterase-5 inhibitor and are indicated for the treatment of erectile dysfunction

    Read More
  • USFDA completes inspection at Lupin’s Tarapur API facility
    23rd Sep 2019, 08:59 AM

    The inspection at the Tarapur facility closed with three observations

    Read More
  • Lupin receives sANDA approval from USFDA for Levothyroxine Sodium Tablets
    20th Sep 2019, 15:55 PM

    The company’s Levothyroxine Sodium Tablets are indicated for Hypothyroidism and Pituitary Thyrotropin Suppression

    Read More
  • Lupin gets warning letter from USFDA for Mandideep (Unit-1) facility
    19th Sep 2019, 10:25 AM

    The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility

    Read More
  • Lupin gets Health Canada’s nod for Propranolol Hydrochloride ER Capsules
    13th Sep 2019, 16:27 PM

    The company is the first generic company to receive an approval for generic Inderal-LA Capsules for the Canadian market

    Read More
  • Lupin receives USFDA's approval for Ethacrynic Acid Tablets
    9th Sep 2019, 15:07 PM

    The company’s Ethacrynic Acid Tablets USP, 25 mg, is the generic version of Edecrin Tablets, 25 mg, of Bausch Health Americas, Inc

    Read More
  • Lupin partners with Boehringer lngelheim
    4th Sep 2019, 12:41 PM

    The partnership aims to develop Lupin's lead MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers

    Read More
  • Lupin’s arm inks commercial agreement with Creso for hemp oil based cannaQIX
    26th Aug 2019, 15:18 PM

    Creso affords Pharma Dynamics sole distribution rights of its organic, broad spectrum hemp oil nutraceutical, cannaQIX10, across South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda

    Read More
  • Lupin’s arm recalling 39,216 bottles of Lisinopril & Hydrochlorothiazide tablets from US
    26th Aug 2019, 10:21 AM

    This tablets were manufactured at the company’s Pithampur facility

    Read More
  • Lupin launches Fluoxetine Tablets USP
    22nd Aug 2019, 15:10 PM

    It is indicated in the treatment of MDD, OCD, Bulimia Nervosa and Panic Disorder

    Read More
  • Lupin divests Kyowa Criticare to Neopharma group
    22nd Aug 2019, 11:09 AM

    Under the terms of the agreement, the company has agreed to sell all the issued and outstanding share capital in Kyowa Criticare to neo ALA

    Read More
  • Lupin receives USFDA's approval for Hydrocortisone Valerate Cream
    16th Aug 2019, 15:29 PM

    It is indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.